Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...

Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end ...

Tolebrutinib belongs to a class of drugs that target microglia through an enzymatic ... Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on how it plans to split ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

A new study reveals how gender disparities cause therapeutic inertia in MS treatment for women, highlighting delays and ...

A study has revealed significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), highlighting gender disparities that could impact long-term health outcomes for women of ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Multiple sclerosis was once thought to primarily affect white people of European ancestry, so many treatments and diagnostic ...